nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00897117,Molecular Fingerprinting of Lung Cancer,,Recruiting,Observational,Lung Cancer,gene expression analysis; microarray analysis; protein expression analysis; biologic sample preservation procedure; laboratory biomarker analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry,,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),4000,2001-05-05,2031-05-31,United States,No,https://clinicaltrials.gov/study/NCT00897117
NCT02143830,"A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine",Phase 2,Recruiting,Interventional,Fanconi Anemia; Severe Marrow Failure; Myelodysplastic Syndrome (MDS); Acute Myelogenous Leukemia (AML),Busulfan; Cyclophosphamide; Fludarabine; rabbit ATG; G-CSF; Peripheral blood stem cell,,"Children's Hospital Medical Center, Cincinnati",Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center,70,2014-04-05,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT02143830
NCT03474497,"UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade",Phase 1/Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Head and Neck Squamous Cell Carcinoma,IL-2; Pembrolizumab; Radiotherapy,,"Megan Daly, MD",Merck Sharp & Dohme LLC,45,2019-05-20,2023-12-05,United States,No,https://clinicaltrials.gov/study/NCT03474497
NCT03476681,Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Cancer,NEO-201 in combination with pembrolizumab,,"Precision Biologics, Inc",,121,2019-01-18,2029-01-15,United States,No,https://clinicaltrials.gov/study/NCT03476681
NCT03551951,"Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening",,Recruiting,Observational,Non Small Cell Lung Cancer; Esophageal Cancer; Gastric Cancer; Pancreatic Cancer; Hepatocellular Cancer; Colorectal Cancer,"Test for circulating tumor cells, DNA alterations",,University of Missouri-Columbia,Harry S. Truman Memorial Veterans' Hospital,320,2016-07-01,2027-12-30,United States,No,https://clinicaltrials.gov/study/NCT03551951
NCT03740256,A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors,Phase 1,Recruiting,Interventional,Bladder Cancer; Head and Neck Squamous Cell Carcinoma; Cancer of the Salivary Gland; Lung Cancer; Breast Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; Pancreatic Adenocarcinoma; Solid Tumor,CAdVEC,,Baylor College of Medicine,The Methodist Hospital Research Institute,45,2020-12-14,2038-12-30,United States,No,https://clinicaltrials.gov/study/NCT03740256
NCT03786692,"TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked",Phase 2,Recruiting,Interventional,"Non-Small Cell Carcinoma of Lung, TNM Stage 4",Arm A; Arm B,,Fox Chase Cancer Center,National Comprehensive Cancer Network,117,2019-09-04,2028-01-05,United States,No,https://clinicaltrials.gov/study/NCT03786692
NCT03851445,LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study),Phase 2/Phase 3,Recruiting,Interventional,Previously Treated Non-Small Cell Lung Cancer,Screening Platform,,SWOG Cancer Research Network,National Cancer Institute (NCI),10000,2019-02-06,2029-01-28,United States,No,https://clinicaltrials.gov/study/NCT03851445
NCT04003649,A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma,Phase 1,Recruiting,Interventional,Recurrent Glioblastoma; Refractory Glioblastoma,IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells; Ipilimumab; Nivolumab; Quality-of-Life Assessment; Questionnaire Administration,,City of Hope Medical Center,National Cancer Institute (NCI); Bristol-Myers Squibb; Gateway for Cancer Research,60,2019-12-02,2026-05-26,United States,No,https://clinicaltrials.gov/study/NCT04003649
NCT04155034,MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK),Phase 3,Recruiting,Interventional,Extensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma,Magnetic Resonance Imaging; Prophylactic Cranial Irradiation,,SWOG Cancer Research Network,National Cancer Institute (NCI),668,2020-05-04,2029-11-15,Canada; Chile; Colombia; Mexico; Saudi Arabia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04155034
NCT04165070,"KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)",Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Pembrolizumab; Carboplatin; Paclitaxel; Pemetrexed; Vibostolimab; Boserolimab; MK-4830; MK-0482; Ifinatamab Deruxtecan (I-DXd); HER3-DXd,,Merck Sharp & Dohme LLC,Daiichi Sankyo,450,2019-12-19,2032-02-13,Hungary; Israel; Italy; Poland; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04165070
NCT04266730,Phase I Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Administered Concurrently With Pembrolizumab,Phase 1,Not yet recruiting,Interventional,Squamous Cell Lung Cancer; Squamous Non-small Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck,PANDA-VAC; Pembrolizumab,,UNC Lineberger Comprehensive Cancer Center,,6,2025-12-22,2033-06-01,United States,No,https://clinicaltrials.gov/study/NCT04266730
NCT04314401,Cancer Moonshot Biobank Research Protocol,,Recruiting,Observational,Acute Myeloid Leukemia; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Carcinoma; Fallopian Tube Carcinoma; Gastric Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Invasive Breast Carcinoma; Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Metastatic Prostate Carcinoma; Multiple Myeloma; Ovarian Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Triple-Negative Breast Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Medical Chart Review; Paracentesis; Positron Emission Tomography,,National Cancer Institute (NCI),,1600,2020-11-11,2027-04-30,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04314401
NCT04389632,A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,"Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck; HER2 Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Ovarian Neoplasms; Cutaneous Squamous Cell Cancer; Exocrine Pancreatic Adenocarcinoma; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Stomach Neoplasms",sigvotatug vedotin; pembrolizumab; cisplatin; carboplatin,,"Seagen, a wholly owned subsidiary of Pfizer",,1006,2020-06-08,2029-03-22,France; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04389632
NCT04423029,"A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications",Phase 1,Recruiting,Interventional,Solid Tumors,DF6002; Nivolumab,,Dragonfly Therapeutics,,438,2020-07-13,2027-11-30,Australia; France; Spain; United States,No,https://clinicaltrials.gov/study/NCT04423029
NCT04429542,"First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors",Phase 1,Recruiting,Interventional,"Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of Anal Canal; Colorectal Cancer; Squamous Cell Carcinoma of the Lung; EGFR Amplification; Epithelial Ovarian Cancer; Pancreas Cancer; Cutaneous Squamous Cell Carcinoma; Head and Neck Neoplasms; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck",BCA101; Pembrolizumab,,Bicara Therapeutics,Merck Sharp & Dohme LLC,292,2020-06-01,2027-06-01,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT04429542
NCT04499053,A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small Cell Lung",Durvalumab; Tremelimumab,,Georgetown University,AstraZeneca,18,2020-12-09,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT04499053
NCT04616248,"A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable Disease",Phase 1,Recruiting,Interventional,"Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8; Unresectable Breast Carcinoma; Metastatic Melanoma; Unresectable Melanoma; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; Soft Tissue Sarcoma; Bone Sarcoma; Sarcoma,Soft Tissue; Sarcoma of Bone; Basal Cell Carcinoma",Anti-CD40 Agonist Monoclonal Antibody CDX-1140; Poly ICLC; Radiation Therapy; Recombinant Flt3 Ligand; Pembrolizumab; Tocilizumab,,University of Southern California,National Institutes of Health (NIH),18,2023-01-09,2027-01-09,United States,No,https://clinicaltrials.gov/study/NCT04616248
NCT04665206,"Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult; Mesothelioma; NSCLC",VT3989; Nivolumab & Ipilimumab; Osimertinib,,"Vivace Therapeutics, Inc",,336,2021-03-24,2027-06-02,Australia; United States,No,https://clinicaltrials.gov/study/NCT04665206
NCT04712877,LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers,,Recruiting,Observational,NSCLC,"ctDNA, tumor NGS",,Lung Cancer Mutation Consortium,Lung Cancer Research Foundation,1000,2022-06-15,2026-06-15,United States,No,https://clinicaltrials.gov/study/NCT04712877
NCT04794699,"An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor,IDE397; Docetaxel; Paclitaxel; Sacituzumab govitecan,,IDEAYA Biosciences,,180,2021-04-14,2027-03-30,Australia; France; Germany; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT04794699
NCT04840589,"Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors",Phase 1,Recruiting,Interventional,Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Platinum-Resistant Ovarian Carcinoma; Refractory Ovarian Carcinoma,BET Bromodomain Inhibitor ZEN-3694; Biopsy Procedure; Biospecimen Collection; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography; X-Ray Imaging,,National Cancer Institute (NCI),,66,2022-02-02,2026-01-01,United States,No,https://clinicaltrials.gov/study/NCT04840589
NCT04868877,"Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer,MCLA-129; Osimertinib; Chemotherapy,,Merus N.V.,,576,2021-04-28,2027-03-05,Belgium; France; Germany; Italy; Netherlands; Singapore; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04868877
NCT04929028,Risk-Adapted Therapy for HIV-Associated Anal Cancer,Phase 2,Recruiting,Interventional,AIDS-Related Anal Carcinoma; Anal Margin Squamous Cell Carcinoma; Anal Non-Keratinizing Squamous Cell Carcinoma; Anal Squamous Cell Carcinoma; HIV Infection; Rectal Squamous Cell Carcinoma; Stage II Rectal Cancer AJCC v8; Stage IIB Anal Cancer AJCC v8; Stage III Anal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8,Anoscopy; Biospecimen Collection; Capecitabine; Colonoscopy; Computed Tomography; Digital Rectal Examination; Echocardiography Test; Fludeoxyglucose F-18; Fluorouracil; Intensity-Modulated Radiation Therapy; Lymph Node Biopsy; Magnetic Resonance Imaging; Mitomycin; Nivolumab; Positron Emission Tomography; Proctoscopy; Questionnaire Administration; Sigmoidoscopy,,National Cancer Institute (NCI),,40,2022-08-09,2029-09-15,United States,No,https://clinicaltrials.gov/study/NCT04929028
NCT05005403,"A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer; Gastric/Esophageal Cancer; High-Grade Serous Ovarian Cancer; Pancreatic Cancer; Triple Negative Breast Cancer,Azirkitug; Budigalimab; Bevacizumab,,AbbVie,,512,2021-11-01,2027-06-05,Israel; Japan; South Korea; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05005403
NCT05058651,Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC),Phase 2/Phase 3,Recruiting,Interventional,Advanced Extrapulmonary Neuroendocrine Carcinoma; Metastatic Extrapulmonary Neuroendocrine Carcinoma; Recurrent Extrapulmonary Neuroendocrine Carcinoma; Unresectable Extrapulmonary Neuroendocrine Carcinoma,Atezolizumab; Biospecimen Collection; Carboplatin; Cisplatin; Computed Tomography; Etoposide; Magnetic Resonance Imaging; Patient Observation,,National Cancer Institute (NCI),,189,2022-06-28,2028-10-01,United States,No,https://clinicaltrials.gov/study/NCT05058651
NCT05061550,"A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)",Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer,Durvalumab; Oleclumab; Monalizumab; Dato-DXd; AZD0171; Carboplatin; Cisplatin; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin; Carboplatin/Paclitaxel; Volrustomig; Rilvegostomig,,AstraZeneca,Parexel,630,2022-04-14,2030-05-09,Belgium; Canada; France; Hungary; Ireland; Italy; Portugal; South Korea; Spain; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT05061550
NCT05098132,A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications,Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; Non Small Cell Lung Cancer; Untreated Advanced NSCLC; 1st Line NSCLC,STK-012; pembrolizumab; pemetrexed; carboplatin,,Synthekine,,364,2022-01-25,2029-01-05,United States,No,https://clinicaltrials.gov/study/NCT05098132
NCT05267626,"A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma; Non-Small Cell Lung Cancer,AU-007; Aldesleukin; Avelumab; Nivolumab,,"Aulos Bioscience, Inc.",,159,2022-04-04,2026-06-12,Australia; United States,No,https://clinicaltrials.gov/study/NCT05267626
NCT05388773,Phase II Trial of Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer,Phase 2,Recruiting,Interventional,Oropharynx Cancer,therapeutic conventional surgery; laboratory biomarker analysis; quality-of-life assessment; intensity-modulated radiation therapy; Cisplatin; Carboplatin,,Heath Skinner,,150,2022-07-20,2030-12-31,United States,No,https://clinicaltrials.gov/study/NCT05388773
NCT05394831,"A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer",Phase 1/Phase 2,Recruiting,Interventional,EGFR Mutant Advanced Non-small Cell Lung Cancer,JIN-A02,,J Ints Bio,,150,2023-07-30,2026-09-30,South Korea; Thailand; United States,No,https://clinicaltrials.gov/study/NCT05394831
NCT05415358,A Prospective Study Of Immune Signatures In Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients At Completion Of Immune Checkpoint Inhibitor Treatment Either As Monotherapy Or In Combination With Chemotherapy In The First Line Setting,,Recruiting,Observational,"Lung Cancer, Nonsmall Cell",Blood and tissue samples,,Wake Forest University Health Sciences,Atrium Health Levine Cancer Institute; Atrium Health Wake Forest Baptist,23,2023-01-17,2035-09-05,United States,No,https://clinicaltrials.gov/study/NCT05415358
NCT05430009,Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Liver Metastases; Non-small Cell Lung Cancer,Liver SBRT; Pembrolizumab,,VA Ann Arbor Healthcare System,LUNGevity Foundation,12,2022-06-17,2026-06-15,United States,No,https://clinicaltrials.gov/study/NCT05430009
NCT05443126,"A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; NSCLC,EP0031,,Ellipses Pharma,,265,2022-09-30,2027-06-05,France; Spain; United Arab Emirates; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05443126
NCT05479812,A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors,Phase 1,Recruiting,Interventional,Metastatic Solid Tumor; Advanced Solid Tumor,WTX-124; pembrolizumab,,"Werewolf Therapeutics, Inc.",Merck Sharp & Dohme LLC,150,2022-05-20,2026-07-31,United States,No,https://clinicaltrials.gov/study/NCT05479812
NCT05501665,SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study,Phase 1/Phase 2,Recruiting,Interventional,Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage III Lung Cancer,Biospecimen Collection; Carboplatin; Computed Tomography; Fludeoxyglucose F-18; Nab-paclitaxel; Pembrolizumab; Pemetrexed; Positron Emission Tomography; Radiation Therapy; [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan; Ipilimumab; Nivolumab; Cemiplimab; Atezolizumab,,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI); Varian Medical Systems,25,2023-05-09,2027-02-01,United States,No,https://clinicaltrials.gov/study/NCT05501665
NCT05519293,"A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients With Active EGFR Mutation Locally Advanced or Metastatic NSCLC",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer,H002,,RedCloud Bio,Parexel,76,2022-12-15,2025-02-28,United States,No,https://clinicaltrials.gov/study/NCT05519293
NCT05566223,A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System,Phase 1/Phase 2,Not yet recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Metastatic Non Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Adenocarcinoma of Lung; Large Cell Lung Cancer",Fludarabine; Cyclophosphamide; CISH Inactivated TIL; Aldesleukin; Pembrolizumab,,"Intima Bioscience, Inc.",,70,2023-02-05,2027-11-05,United States,No,https://clinicaltrials.gov/study/NCT05566223
NCT05592626,"A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumors; Genital Neoplasm, Female; Urogenital Neoplasms; Lung Neoplasm; Neoplasms by Site; Papillomavirus Infection; Epstein-Barr Virus Infections; Carcinoma; Neoplasms; Vulvar Neoplasms; Vulvar Diseases; Abdominal Neoplasm",STAR0602,,"Marengo Therapeutics, Inc.",,365,2023-01-04,2026-10-05,Canada; France; Spain; United States,No,https://clinicaltrials.gov/study/NCT05592626
NCT05651022,"A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult; HCC - Hepatocellular Carcinoma; CRC (Colorectal Cancer); Pancreatic Adenocarcinoma; NSCLC Non-small Cell Lung Cancer; Squamous Cell Cancer of the Head and Neck; UC (Urothelial Cancer); MSI-H Cancer",Decoy20; Tislelizumab,,"Indaptus Therapeutics, Inc",Translational Drug Development,120,2023-02-28,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT05651022
NCT05671510,"Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors",Phase 3,Recruiting,Interventional,Non Small Cell Lung Cancer,Gotistobart; Docetaxel,,"OncoC4, Inc.",BioNTech SE,600,2023-06-28,2027-06-30,Australia; Belgium; Canada; China; Germany; Italy; Netherlands; South Korea; Spain; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05671510
NCT05673200,Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer,Phase 1,Recruiting,Interventional,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Decitabine and Cedazuridine; Magnetic Resonance Imaging; Paclitaxel; Pembrolizumab,,National Cancer Institute (NCI),,32,2023-09-25,2027-02-23,United States,No,https://clinicaltrials.gov/study/NCT05673200
NCT05684965,"A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,XTX301,,"Xilio Development, Inc.",,358,2023-05-11,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT05684965
NCT05715229,A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Nivolumab; Ipilimumab; Carboplatin; Paclitaxel; Pemetrexed,,Hackensack Meridian Health,MedSIR,108,2023-09-29,2026-04-28,United States,No,https://clinicaltrials.gov/study/NCT05715229
NCT05736029,"PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.",,Recruiting,Observational,Non Small Cell Lung Cancer; Healthy,"blood, stool and tissue samples collection",,OncoHost Ltd.,,350,2022-11-07,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT05736029
NCT05797246,A Phase II Study of Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP),Phase 2,Recruiting,Interventional,"Respiratory Tract Diseases; Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Squamous Cell; Tumor Virus Infections; Infections; Virus Diseases; DNA Virus Infections; Pathologic Processes; Disease Attributes; Recurrence; Papilloma; Respiratory Tract Infections; Papillomavirus Infections",Bevacizumab,,National Cancer Institute (NCI),,50,2023-08-02,2029-01-01,United States,No,https://clinicaltrials.gov/study/NCT05797246
NCT05799274,Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors,Phase 1,Recruiting,Interventional,Healthy Volunteers; Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Esophageal Squamous Cell Carcinoma; Cervical Cancer; Endometrial Cancer; Ovarian Cancer,RAD301 ([68Ga]-RAD301),,"Radiopharm Theranostics, Ltd",,9,2023-11-09,2025-11-05,United States,No,https://clinicaltrials.gov/study/NCT05799274
NCT05800587,Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities,Phase 2,Recruiting,Interventional,Lung Cancer; Small-cell Lung Cancer; Non Small Cell Lung Cancer,Carboplatin; Pemetrexed; Paclitaxel; Nab paclitaxel; Docetaxel; Gemcitabine; Etoposide; Irinotecan; Topotecan; Lurbinectedin,,Fox Chase Cancer Center,,280,2023-02-22,2029-08-01,United States,No,https://clinicaltrials.gov/study/NCT05800587
NCT05853575,A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung,Adagrasib,,Mirati Therapeutics Inc.,,200,2024-02-16,2026-07-30,Brazil; Croatia; France; Greece; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Romania; Serbia; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT05853575
NCT05866302,"Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients. A Multi-center, Observational Trial.",,Recruiting,Observational,Chronic Lung Disease; Hematopoietic Cell Transplantation; Graft Versus Host Disease,,,University of Michigan Rogel Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)",375,2023-05-30,2028-05-05,United States,No,https://clinicaltrials.gov/study/NCT05866302
NCT05877599,"An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Carcinoma; Pancreatic Adenocarcinoma; Breast Cancer; Other Solid Tumors; Ovarian Cancer,"Autologous, engineered T Cells targeting TP53 R175H",,AstraZeneca,,162,2023-07-12,2039-08-01,United States,No,https://clinicaltrials.gov/study/NCT05877599
NCT05983133,A Phase 1 Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,"Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of the Head and Neck; Pancreatic Ductal Adenocarcinoma",PF-08046052,,"Seagen, a wholly owned subsidiary of Pfizer",,290,2023-11-14,2030-01-09,United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05983133
NCT05985655,"A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Breast Carcinoma; High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC); Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma",GTAEXS617; SoC,,"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",,165,2023-07-06,2028-05-05,Belgium; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05985655
NCT06014255,A Phase 2 Randomized Trial of Neoadjuvant Enoblituzumab Versus Standard of Care in Men With High-Risk Localized Prostate Cancer: The Help Elucidate & Attack Longitudinally (HEAT) Prostate Cancer Randomized Study,Phase 2,Recruiting,Interventional,Prostate Cancer,Enoblituzumab; Standard of Care,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,MacroGenics,219,2024-02-16,2029-03-01,United States,No,https://clinicaltrials.gov/study/NCT06014255
NCT06047379,"An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.",Phase 1/Phase 2,Recruiting,Interventional,"Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult; Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Head and Neck Squamous Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Microsatellite Instability-High Solid Malignant Tumor; Mismatch Repair Deficient Solid Malignant Tumor; Microsatellite Instability-High Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Small Cell Lung Cancer; Squamous Cell Carcinoma; Urothelial Carcinoma",NEO212 Oral Capsule; Ipilimumab; Pembrolizumab; Nivolumab; Regorafenib; Carboplatin; Paclitaxel; FOLFIRI Protocol; Bevacizumab,,"Neonc Technologies, Inc.",,134,2023-11-01,2027-08-31,United States,No,https://clinicaltrials.gov/study/NCT06047379
NCT06119581,"SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis",LY3537982; Pembrolizumab; Placebo; Cisplatin; Carboplatin; Pemetrexed,,Eli Lilly and Company,,1016,2023-12-21,2029-10-05,Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Greece; Hungary; India; Italy; Japan; Mexico; Netherlands; Norway; Poland; Portugal; Romania; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06119581
NCT06131840,An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors,Phase 1,Recruiting,Interventional,"Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms; Pancreatic Ductal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Small Cell Lung Carcinoma",PF-08046050; bevacizumab; 5-Fluorouracil (5-FU); Oxaliplatin; Leucovorin (LV),,"Seagen, a wholly owned subsidiary of Pfizer",Sanofi,914,2023-11-20,2030-09-12,Canada; France; Netherlands; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06131840
NCT06150664,"A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies",Phase 1,Recruiting,Interventional,Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Hodgkin Lymphoma; Head and Neck Squamous Cell Carcinoma; Malignant Melanoma,CTX-8371,,Compass Therapeutics,,73,2024-03-19,2027-05-05,United States,No,https://clinicaltrials.gov/study/NCT06150664
NCT06162572,"A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC),S095018; S095024; S095029; S095018 Recommended Dose Expansion (RDE); S095024 RDE; S095029 RDE; Cemiplimab,,Servier Bio-Innovation LLC,Institut de Recherches Internationales Servier; Regeneron Pharmaceuticals,176,2024-08-07,2027-07-05,Argentina; Australia; Austria; Belgium; Brazil; France; Hong Kong; Hungary; Italy; Romania; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06162572
NCT06177106,An Assessment of Acute Solar UV-induced PD-L1/PD1 Expression in Sun Damaged & Sun Protected Human Skin of Participants With and Without History of SCC,Not Applicable,Recruiting,Interventional,Other Skin Changes Due to Chronic Exposure to Nonionizing Radiation,Solar Simulated Light,,University of Arizona,National Cancer Institute (NCI),46,2023-12-26,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT06177106
NCT06228066,A Phase II Study of Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER),Phase 2,Recruiting,Interventional,Small Cell Carcinoma of the Bladder; High Grade Neuroendocrine Tumors of the Urinary Tract,Lurbinectedin; Avelumab,,National Cancer Institute (NCI),,45,2024-06-13,2028-09-01,United States,No,https://clinicaltrials.gov/study/NCT06228066
NCT06242470,"A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer; Breast Cancer; Ovarian Cancer; Esophageal Squamous Cell Cancer (SCC),MGC026 Dose Escalation; MGC026 Dose for Expansion,,MacroGenics,,250,2024-03-06,2028-10-05,Australia; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06242470
NCT06246110,A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer,Phase 2,Recruiting,Interventional,NSCLC,EIK1001; Pembrolizumab; Paclitaxel; Pemetrexed; Carboplatin,,Eikon Therapeutics,,70,2024-02-06,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06246110
NCT06262321,Phase II Trial of Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax,Phase 2,Recruiting,Interventional,Stage 4 NSCLC; Radiotherapy,Prophylactic Palliative Radiotherapy,,University of Rochester,,48,2024-05-15,2029-02-01,United States,No,https://clinicaltrials.gov/study/NCT06262321
NCT06270706,"A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab",Phase 1,Recruiting,Interventional,Metastatic Solid Tumor,PLN-101095; Pembrolizumab,,"Pliant Therapeutics, Inc.",,77,2023-08-30,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT06270706
NCT06312176,"An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer",Phase 3,Recruiting,Interventional,Breast Neoplasms,Sacituzumab tirumotecan; Pembrolizumab; Paclitaxel; Nab-paclitaxel; Capecitabine; Liposomal doxorubicin,,Merck Sharp & Dohme LLC,,1200,2024-04-14,2031-04-12,Argentina; Australia; Belgium; Brazil; Canada; Chile; Colombia; Costa Rica; Czechia; Denmark; France; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Peru; Philippines; Poland; Portugal; Puerto Rico; Romania; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06312176
NCT06332755,"A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC); Renal Cell Carcinoma(RCC); Urothelial Carcinoma; Malignant Melanoma,Phase 1a: LB-LR1109; Phase 1b: LB-LR1109 and Atezolizumab,,LG Chem,,76,2024-06-05,2028-03-05,United States,No,https://clinicaltrials.gov/study/NCT06332755
NCT06343402,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma,BBO-8520; Pembrolizumab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,250,2024-05-22,2028-02-05,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06343402
NCT06422143,Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer,Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer; NSCLC,Pembrolizumab; sac-TMT; Carboplatin; Paclitaxel; Nab-paclitaxel,,Merck Sharp & Dohme LLC,,851,2024-06-10,2031-02-12,Argentina; Austria; Brazil; Canada; Chile; China; Colombia; Czechia; France; Germany; Hungary; Ireland; Israel; Italy; Japan; Peru; Poland; Romania; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Arab Emirates; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06422143
NCT06452277,"A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations",Phase 3,Recruiting,Interventional,Advanced Non-small Cell Lung Cancer; HER2 Mutation,BAY2927088; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed,,Bayer,,278,2024-08-28,2029-06-27,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Czechia; Denmark; Finland; France; Germany; Greece; Hong Kong; Hungary; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Poland; Portugal; Romania; Singapore; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); Ukraine; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06452277
NCT06475807,Cancer Nutrition Study: CaNS - A Pilot Study of Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors,Not Applicable,Recruiting,Interventional,Cancer,High-fermented food; High fiber supplementation,,University of Pittsburgh,,60,2024-07-17,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT06475807
NCT06508034,Probiotics Preventing Immune Checkpoint Inhibitor-Induced Colitis,Not Applicable,Recruiting,Interventional,Malignant Solid Neoplasm,Biospecimen Collection; Live Freeze-Dried Lactic Acid Bacteria Probiotic; Questionnaire Administration,,Mayo Clinic,,12,2024-07-31,2027-08-30,United States,No,https://clinicaltrials.gov/study/NCT06508034
NCT06524544,A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer,Phase 3,Recruiting,Interventional,Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Biospecimen Collection; Carboplatin; Cisplatin; Computed Tomography; Docetaxel; Gemcitabine; Magnetic Resonance Imaging; Paclitaxel; Pembrolizumab; Questionnaire Administration; Sacituzumab Govitecan,,National Cancer Institute (NCI),,320,2025-12-02,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT06524544
NCT06525220,"A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma",Phase 3,Recruiting,Interventional,Head and Neck Squamous Cell Carcinoma,Petosemtamab; Pembrolizumab,,Merus N.V.,,500,2024-09-25,2030-07-05,Argentina; Australia; Belgium; Brazil; Canada; Chile; France; Germany; Greece; Israel; Italy; Japan; Malaysia; Netherlands; Poland; Portugal; South Korea; Spain; Taiwan; Thailand; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06525220
NCT06526819,"An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,SMP3124LP,,"Sumitomo Pharma America, Inc.",,120,2024-08-14,2029-05-05,Japan; United States,No,https://clinicaltrials.gov/study/NCT06526819
NCT06548672,"A Phase Ia/Ib, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients With Locally Advanced or Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Cancer; Metastatic Solid Tumor,BC3195,,"Biocity Biopharmaceutics Co., Ltd.",,148,2024-06-24,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT06548672
NCT06555744,"A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,ZW191,,Zymeworks BC Inc.,,145,2024-10-30,2027-01-05,Australia; Japan; Singapore; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06555744
NCT06562192,"Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; HR+/HER2- Ductal and Lobular Breast Cancer; Triple Negative Breast Cancer; Colorectal Cancer,[68Ga]Ga-NNS309; [177Lu]Lu-NNS309,,Novartis Pharmaceuticals,,162,2024-10-15,2031-01-16,Belgium; Canada; France; Germany; Israel; Italy; Netherlands; Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06562192
NCT06644768,"A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Lung Cancer,valemetostat tosylate; pembrolizumab,,Daiichi Sankyo,Merck Sharp & Dohme LLC,137,2024-10-30,2030-04-30,Argentina; Brazil; China; Japan; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06644768
NCT06660407,Grid Radiotherapy for Advanced Non-Small Cell Lung Cancer at the Time of Progression on Immune Checkpoint Inhibition,Phase 2,Recruiting,Interventional,Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection; Computed Tomography; Immunotherapy; Palliative Radiation Therapy; Spatially-fractionated Radiation Therapy,,Mayo Clinic,,20,2024-11-14,2027-01-10,United States,No,https://clinicaltrials.gov/study/NCT06660407
NCT06667076,"A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Amivantamab; Lazertinib; Chemotherapy: Pemetrexed; Chemotherapy: Carboplatin,,"Janssen Research & Development, LLC",,480,2024-12-16,2030-12-26,Finland; Greece; Israel; Poland; Puerto Rico; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06667076
NCT06692738,"A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,Rilvegostomig; Pembrolizumab; Carboplatin; Paclitaxel; Nab-paclitaxel,,AstraZeneca,,880,2024-11-18,2029-10-08,Argentina; Australia; Austria; Belgium; Brazil; Canada; China; France; Germany; Hungary; India; Italy; Japan; Malaysia; Netherlands; Peru; Poland; Puerto Rico; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT06692738
NCT06706076,"A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)",Phase 1/Phase 2,Recruiting,Interventional,NSCLC (Advanced Non-small Cell Lung Cancer),BH-30643; BH-30643,,BlossomHill Therapeutics,,266,2025-01-09,2029-07-31,Australia; Canada; Hong Kong; Japan; Malaysia; Singapore; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06706076
NCT06710223,A Phase Ib Study of Cryoablation and Pressure-enabled Hepatic Arterial Infusion of Class C Toll-like Receptor 9 Agonist SD-101 in Combination with Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma,Phase 1,Recruiting,Interventional,Hepatocellular Carcinoma,SD-101; Cryotherapy; Tremelimumab; Durvalumab,,"University of California, San Diego","TriSalus Life Sciences, Inc.",20,2025-01-03,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT06710223
NCT06712316,"A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer",Phase 2/Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,Pumitamig; Pembrolizumab; Carboplatin; Pemetrexed; Paclitaxel,,BioNTech SE,Biotheus Inc.,982,2025-01-07,2030-12-05,Australia; Belgium; China; France; Germany; Italy; Poland; Romania; South Korea; Spain; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06712316
NCT06730750,"A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumors,BMS-986490; Bevacizumab,,Bristol-Myers Squibb,,360,2025-02-12,2029-12-09,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06730750
NCT06747585,"A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Squamous Non-small-cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma,ALE.P02,,Alentis Therapeutics AG,,170,2024-12-16,2028-08-15,France; Hong Kong; Italy; Singapore; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06747585
NCT06778863,GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation,Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Colorectal Adenocarcinoma; Pancreatic Adenocarcinoma; Lung Cancer; Ovarian Cancer; Breast Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Bladder Cancer,CLSP-1025,,"Clasp Therapeutics, Inc.",,90,2025-02-28,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT06778863
NCT06788912,KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC),Phase 2,Recruiting,Interventional,Lung Neoplasm Malignant,Pembrolizumab (neoadjuvant); Cisplatin; Gemcitabine; Pemetrexed; Sacituzumab tirumotecan; H1 receptor antagonist; H2 receptor antagonist; Acetaminophen (or equivalent); Dexamethasone (or equivalent); Carboplatin; Pembrolizumab (adjuvant); Paclitaxel; Steroid mouthwash (dexamethasone or equivalent),,Merck Sharp & Dohme LLC,,60,2025-03-20,2032-02-06,Chile; Greece; Hungary; Italy; Poland; Spain; Turkey (Türkiye); Ukraine; United States,No,https://clinicaltrials.gov/study/NCT06788912
NCT06789172,"A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumours; Sarcoma; HNSCC; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; NSCLC; Pancreatic Adenocarcinoma; Colorectal Cancer (CRC); Myxofibrosarcoma (MFS); Solitary Fibrous Tumors; Dedifferentiated Liposarcoma; Undifferentiated Pleomorphic Sarcoma (UPS),OKN4395; Pembrolizumab; Fasting; Fed; H2 Receptor Antagonist,,Epkin,Precision For Medicine,166,2025-01-23,2028-09-05,Australia; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06789172
NCT06810544,"A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss",Phase 1/Phase 2,Recruiting,Interventional,"Non Small Cell Lung Cancer; Glioma Glioblastoma Multiforme; Glioma, Malignant; Solid Tumor; Non-Small Cell Adenocarcinoma; Lung Cancer; Brain Tumor",TNG456; abemaciclib,,"Tango Therapeutics, Inc.",Eli Lilly and Company,191,2025-03-24,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT06810544
NCT06841354,"A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)",Phase 3,Recruiting,Interventional,Triple Negative Breast Neoplasms,Sacituzumab tirumotecan; Pembrolizumab; Rescue Medication; Paclitaxel; Nab-paclitaxel; Gemcitabine; Carboplatin,,Merck Sharp & Dohme LLC,,1000,2025-03-16,2030-05-18,Argentina; Australia; Belgium; Brazil; Canada; Chile; China; Colombia; Czechia; Denmark; Finland; France; Germany; Greece; Hungary; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Peru; Philippines; Poland; Romania; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06841354
NCT06860815,Pilot Study of Cemiplimab and Hepatic Radioembolization in Patients With Liver Dominant Metastatic Breast Cancer,Phase 2,Recruiting,Interventional,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Carcinoma in the Liver,Biopsy; Biospecimen Collection; Cemiplimab; Computed Tomography; Magnetic Resonance Imaging; Transarterial Radioembolization; Yttrium Y 90 Resin Microspheres,,City of Hope Medical Center,National Cancer Institute (NCI),11,2025-12-12,2027-01-03,United States,No,https://clinicaltrials.gov/study/NCT06860815
NCT06865339,TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer,Phase 2,Recruiting,Interventional,NSCLC; Locally Advanced,Cemiplimab; Fianlimab; Radiotherapy; Platinum Doublet Chemotherapy (PDC),,Nitin Ohri,Regeneron Pharmaceuticals; Henry Ford Health System; NYU Langone Health; University of Michigan,76,2025-08-07,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT06865339
NCT06881784,"RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC",Phase 3,Recruiting,Interventional,NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer),daraxonrasib; docetaxel,,"Revolution Medicines, Inc.",,420,2025-05-06,2030-12-01,Australia; Belgium; France; Germany; Hong Kong; Ireland; Italy; Japan; Netherlands; Poland; Puerto Rico; Singapore; South Korea; Spain; Switzerland; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06881784
NCT06907615,"An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)",Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer,HLX43 DOSE 1 (2.0 mg/kg); HLX43 DOSE 2 (2.5 mg/kg),,Shanghai Henlius Biotech,Henlius USA Inc.,243,2025-06-09,2028-06-04,China; United States,No,https://clinicaltrials.gov/study/NCT06907615
NCT06941857,"A Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naïve, Metastatic Pancreatic Cancer",Phase 2,Recruiting,Interventional,Pancreatic Cancer,Oxaliplatin; Irinotecan; Folinic Acid; 5-Fluorouracil (5-FU); NC410; Nivolumab; Ipilimumab,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"NextCure, Inc.; Lustgarten Foundation",20,2025-09-04,2030-09-05,United States,No,https://clinicaltrials.gov/study/NCT06941857
NCT06945484,PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study,Not Applicable,Not yet recruiting,Interventional,"NSCLC Stage II; NSCLC, Stage III",Precision Exercise Regimen for Cancer Care (PERCC),,University of Utah,,20,2025-12-05,2030-12-05,United States,No,https://clinicaltrials.gov/study/NCT06945484
NCT06966700,"A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer",Phase 3,Recruiting,Interventional,Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms,Sacituzumab tirumotecan; Pembrolizumab; Rescue Medication; Carboplatin; Paclitaxel; Doxorubicin; Epirubicin; Cyclophosphamide; Capecitabine; Olaparib,,Merck Sharp & Dohme LLC,,2400,2025-06-30,2034-12-29,Argentina; Australia; Belgium; Brazil; Canada; China; Colombia; Finland; France; Guatemala; Hong Kong; Israel; Japan; Malaysia; Peru; Poland; Portugal; Singapore; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Ukraine; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06966700
NCT06975293,"Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Non-small Cell Lung Cancer; Metastatic Melanoma; Metastatic Endometrial Cancer; Metastatic Head-and-neck Squamous-cell Carcinoma; Solid Tumor,STC-15 in combination with toripalimab,,STORM Therapeutics LTD,"Coherus Oncology, Inc.",188,2025-05-05,2026-01-29,United States,No,https://clinicaltrials.gov/study/NCT06975293
